K-Glim-M Forte 1mg Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This dual mechanism addresses both insulin deficiency and insulin resistance, making K-Glim-M Forte effective in patients inadequately controlled by diet, exercise, and monotherapy. The prolonged-release formulation ensures a steady plasma concentration, minimizing fluctuations and enhancing patient compliance through once-daily dosing. It is essential to initiate therapy with appropriate lifestyle modifications and monitor blood glucose regularly to avoid hypoglycemia, a potential adverse effect associated with sulfonylureas. Contraindications include severe renal impairment, metabolic acidosis, and conditions predisposing to hypoxia. Caution is advised in patients with hepatic dysfunction or cardiovascular disease. Regular assessment of renal function and lactic acidosis symptoms is recommended during treatment. K-Glim-M Forte should be prescribed under medical supervision, with dosage adjustments tailored to individual patient response and tolerability to optimize glycemic control and reduce the risk of diabetes-related complications.